Skip to main content

Table 1 CONTEXT patient cohorts for the MS discovery and validation studies

From: Subclinical effects of remote ischaemic conditioning in human kidney transplants revealed by quantitative proteomics

Patient cohort for the MS discovery studya

Patient cohort for validation study

Recipient

RIC (n =  6)

Non-RIC (n =  6)

Recipient

RIC, n = 72

Non-RIC, n = 74

Gender

Gender

 Male

5

5

 Male

46 (64%)

44 (59%)

 Female

1

1

 Female

26 (36%)

30 (51%)

Age, median (range)

52.2 (43.6–60.5)

48.0 (30.1–70.3)

Age, median (range)

57.3 (49.7–64.8)

60.8 (49.4–65.9)

Dialysis mode

Dialysis mode

 Pre-emptive

3

4

 Preemptive

13 (18%)

15 (20%)

 HD

2

1

 HD

40 (56%)

42 (57%)

 PD

1

1

 PD

18 (25%)

16 (22%)

   

 HD + PD

1 (1%)

1 (1%)

Number of transplant

Number of transplant

 First

6

6

 First

63 (88%)

65 (88%)

 Retransplant

0

0

 Retransplant

9 (13%)

9 (12%)

Original renal disease

Original renal disease

 Glomerulopathy

2

1

 Glomerulopathy

20 (28%)

15 (20%)

 ADPKD

2

2

 ADPKD

15 (21%)

15 (20%)

 Diabetes mellitus

1

1

 Diabetes mellitus

8 (11%)

8 (11%)

 Vascular/hypertension

0

1

 Vascular/hypertension

7 (10%)

9 (12%)

 Reflux/obstructive

0

0

 Reflux/obstructive

3 (4%)

2 (3%)

 Other

0

1

 Other

6 (8%)

7 (9%)

 Unknown

1

0

 Unknown

13 (18%)

18 (24%)

Comorbidity

Comorbidity

 Diabetes mellitus

1

1

 Diabetes mellitus

12 (17%)

14 (19%)

 Hypertension

5

5

 Hypertension

62 (86%)

69 (93%)

Total HLA-A, D, DR mismatches

Total HLA-A, B, DR mismatches

 0

0

0

 0

3 (4%)

6 (8%)

 1–2

0

0

 1–2

15 (21%)

18 (24%)

 3–4

5

6

 3–4

47 (65%)

35 (47%)

 5–6

1

0

 5–6

7 (10%)

15 (20%)

Immunosuppression at discharge

Immunosuppression at discharge

 Tacrolimus

6

6

 Tacrolimus

63 (88%)

72 (97%)

 Mycophenolate mofetil

6

6

 Mycophenolate mofetil

70 (97%)

74 (100%)

 Corticosteroids

6

6

 Corticosteroids

66 (92%)

72 (97%)

   

 Cyclosporine

7 (10%)

2 (3%)

   

 None (graft loss)

2

 

Patient cohort for the MS discovery studya

Patient cohort for validation study

Donor

RIC (n =  6)

Non-RIC (n =  6)

Donor

RIC, n = 72

Non-RIC, n = 74

Gender

Gender

 Male

4

4

 Male n (%)

39 (54%)

41 (55%)

 Female

2

2

 Female n (%)

33 (46%)

33 (45%)

Age, median (range)

61.5 (55–72)

61.5 (55–72)

Age, median (range)

58.5 (50.5–65.5)

56.5 (49–63)

Paired kidneys

6

6

Paired kidneys

28 (39%)

28 (38%)

   

Single kidneys

44 (61%)

46 (62%)

DBD

6

6

DBD

67 (93%)

69 (93%)

   

DCD

5 (7%)

5 (7%)

Cause of death

Cause of death, DBD (n = 67 and 69)

 Cerebrovascular insult

5

5

 Cerebrovascular insult

42 (63%)

43 (62%)

   

 Cerebral anoxia

15 (22%)

17 (25%)

 Trauma

1

1

 Trauma

9 (13%)

9 (13%)

   

 Benign cerebral neoplasm

1 (1%)

0

   

Cause of death, DCD (n = 5 and 5)

  
   

 Cerebrovascular insult

2

2

   

 Cardiac disease

1

2

   

 Trauma

0

1

   

 Other

2

0

Preservation solution

Preservation solutions

 Custodiol

5

5

 Custodiol

56 (78%)

52 (70%)

 UW

1

1

 UW

15 /21%)

20 (27%)

   

 Other

1 (1%)

2 (3%)

  

Warm ischemia time DCD, min

20 (15–25)

18 (14–25)

Cold ischemia time (h) Median (range)

12.3 (5.5–26.2)

13.5 (8.4–21.0)

Cold ischemia time (h) DBD + DCD

 
  

 n > 24 h

13.4 (3.8)

13.9 (4.9)

   

 Missing data

1

4

    

1

1

Total surgery time (h) Median (range)

2.1 (1.7–2.3)

2.3 (1.3–2.6)

Total surgery time (h) Median (range)

2.4 (2.0–2.8)

2.5 (2.0–3.0)

   

 Missing data

1

0

Remuzzi score, median (range)

Remuzzi score, median (range)

 All biopsies

2.5 (1–7) n = 6

3.5 (2–6) n = 6

 All biopsies (n = 61 and 63)

2 (1–3)

2 (1–4)

 6 glom

2.5 (1–7) n = 6

3.5 (2–6) n = 6

 6 glom (n = 56 and 55)b

2 (1–3)

2 (1–4)

 10 glom

3 (2–4) n = 3

3.5 (2–4) n = 4

 10 glom (n = 41 and 42)b

2 (1–3)

2 (1–4)

  

 Missing datac

11 (15%)

11 (15%)

  1. Data are mean (standard deviation), n (%), or median (interquartile range). Remuzzi scores on biopsies taken 30 min after reperfusion of the graft (baseline-biopsy)
  2. Patient demographics and intraoperative data in RIC and non-RIC groups: left side two columns are the exploratory groups and right side two columns are the validation groups. Data are mean (standard deviation), n (%), or median (interquartile range). Remuzzi scores on biopsies taken 30 min after reperfusion of the graft (baseline-biopsy)
  3. HD haemodialysis; PD peritoneal dialysis, ADPKD autosomal dominant polycystic kidney disease, DBD donation after brain death, DCD donation after circulatory death, glom glomeruli, RIC remote ischaemic conditioning, UW University of Wisconsin solution
  4. aSamples used for the discovery cohort are included in the validation cohort
  5. bScore if including only biopsies with minimum 6 or 10 glomeruli in the analysis
  6. cBiopsies were either not performed or insufficient